A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This important study is for adults with a specific type of advanced lung cancer. This cancer has a particular change in their genes called an EGFR sensitizing mutation, and it's either locally advanced (meaning it's spread a bit but can't be fully removed with surgery or radiation) or has spread further in the body (metastatic). The study wants to find out if a new treatment, lazertinib, is more effective and safer than a current standard treatment, gefitinib. Researchers will be carefully checking how long people on each drug live without their cancer growing, and also looking at side effects and their quality of life. This is a vital step in finding better treatments for lung cancer.
At a glance
What is this study about?
Imagine your body is like a complex machine, and sometimes, a part of it, like a gene, can change. In this type of lung cancer, called non-small cell lung cancer with an EGFR sensitizing mutation, this gene change can make the cancer cells grow and spread faster. Doctors are always looking for new and better ways to tackle these cancer cells.
This study is testing a new medicine called lazertinib. It's designed to specifically target and block the signals that tell these particular cancer cells to grow. Think of it like a special key that only fits certain locks. Researchers want to compare lazertinib to gefitinib, which is a medicine that doctors already use for this type of lung cancer. By doing this comparison, they can see which drug is better at stopping the cancer from getting worse and how it affects people's overall well-being.
Finding out if lazertinib is more effective or has fewer side effects than current treatments could mean new hope for people living with this cancer. Studies like this are how we learn and develop new medicines that can improve lives. It’s a very important step in improving future care for lung cancer patients.
Key takeaways
- This study compares a new drug (lazertinib) to a standard drug (gefitinib) for advanced lung cancer.
- It's for non-small cell lung cancer with a specific 'EGFR sensitizing mutation'.
- The main goal is to see if the new drug stops cancer growth for longer and is safe.
- You would receive one of the study drugs, but you and your doctor won't know which one.
- Regular hospital visits, scans, and questionnaires will be part of participation.
- The study aims to find better future treatments for this type of lung cancer.
Who may be eligible?
This study is looking for adults who have a specific type of lung cancer. It's called non-small cell lung cancer, and it has a particular genetic change known as an EGFR sensitizing mutation. This cancer must also be considered 'locally advanced' (meaning it's grown into nearby areas and surgery or radiation wouldn't be enough to cure it) or 'metastatic' (meaning it has spread to other parts of the body).
Essentially, if you're an adult aged 18 or over and have this specific advanced lung cancer that doctors can't cure with surgery or radiotherapy, you might be suitable for this study. Both men and women are welcome to take part.
- Are you 18 years old or older?
- Do you have non-small cell lung cancer?
- Does your cancer have an 'EGFR sensitizing mutation'?
- Is your cancer 'locally advanced' or has it 'spread to other parts of your body' (metastatic)?
- Have your doctors said your cancer cannot be cured with surgery or radiotherapy alone?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to join this study, you'll be given either lazertinib or gefitinib. You won't know which one you're getting, and neither will your doctor – this helps keep the study fair. You'll need to visit the hospital regularly for check-ups, where doctors will assess your health, monitor your cancer with scans, and ask about any side effects you might be having. They will also take blood and, for some, spinal fluid samples to see how the drug is working in your body. You'll also be asked to fill out questionnaires about your quality of life. The study will continue for as long as the treatment is helping you, followed by a follow-up period to check on your long-term health. The total duration of your participation will depend on how you respond to the treatment and the follow-up plan.
Potential risks and benefits
Locations (2)
- —Hungary
- —Greece
Common questions
What kind of lung cancer is this study for?
It's for a specific type of non-small cell lung cancer that has a special genetic change called an EGFR sensitizing mutation. It also needs to be advanced, meaning it can't be cured by surgery or radiation.
What is 'locally advanced' or 'metastatic' cancer?
Locally advanced means the cancer has grown into nearby areas but can't be completely removed. Metastatic means it has spread to other parts of your body.
What are lazertinib and gefitinib?
They are both medications used to treat this type of lung cancer. Lazertinib is a newer drug being tested against gefitinib, which is already a standard treatment.
Will I know which drug I'm getting?
No, you won't know if you're getting lazertinib or gefitinib, and neither will your study doctor. This is done to make sure the study results are fair and unbiased.
What does 'quality of life' mean in this study?
Researchers will ask you to fill out questionnaires to understand how the treatment is affecting your daily life, your symptoms, and your general well-being.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.